Top 10 GLP-1 Plateau Questions from Reddit, Answered

Question 1

Why has my weight loss stalled after 6 months on a GLP-1?

Accepted Answer

The trial data show that weight loss on GLP-1s is not linear and that nearly every patient hits a flattening curve. In STEP 1, semaglutide 2.4 mg drove the steepest weight loss in the first 20 weeks, slowed between weeks 20 and 60, and reached a near-plateau by week 60-68, with a mean total loss of 14.9% at week 68 (Wilding 2021, PMID 33567185). SURMOUNT-1 showed the same S-shaped curve on tirzepatide: steep drop early, slower loss months 6-12, and a flatter tail to month 17, with mean loss of 20.9% on the 15 mg dose (Jastreboff 2022, PMID 35658024). Two-year follow-up in STEP 5 confirmed that most of the additional loss after month 12 was small, and weight stabilized at approximately 15.2% below baseline at 104 weeks (Garvey 2022, PMID 36216945). Plateau at month 6-12 is not failure of the drug, it is the published trajectory. Plateau at a much lower starting BMI (a 22 BMI patient losing only 4-5% before stalling) is a different pattern that warrants a clinician conversation about whether the medication is still indicated. None of this is medical advice.

Question 2

Is a plateau on a GLP-1 the same thing as tachyphylaxis?

Accepted Answer

Tachyphylaxis means receptors stop responding to the same dose of a drug, and the trial data do not support that interpretation for GLP-1s used at maintenance doses. In the STEP 4 maintenance trial, patients who continued semaglutide 2.4 mg from week 20 through week 68 lost an additional 7.9% on top of their run-in loss, while patients switched to placebo regained 6.9% over the same window (Rubino 2021, PMID 33755728). If the receptors had truly desensitized, the continued-treatment arm should not have kept losing. SURMOUNT-4 showed the same pattern on tirzepatide: patients randomized to continue the drug after a 36-week lead-in lost another 5.5% through week 88, while the placebo-switched group regained 14% (Aronne 2024, PMID 38078870). In STEP 5, the curve flattened by month 12 but did not reverse, with weight remaining 15.2% below baseline at 2 years (Garvey 2022, PMID 36216945). A flat curve is the drug holding the loss, not the receptors quitting. Data suggest most apparent stalls reflect the body reaching a new energy balance at the lower weight rather than loss of drug effect.

Question 3

Will increasing my GLP-1 dose break my plateau?

Accepted Answer

Sometimes yes. In SURMOUNT-1, the 5 mg, 10 mg and 15 mg tirzepatide arms produced 16.0%, 21.4% and 22.5% mean weight loss respectively at 72 weeks, with a clear dose-response in both speed and final magnitude (Jastreboff 2022, PMID 35658024). The pattern was similar in STEP, where 2.4 mg outperformed 1.0 mg and 0.5 mg semaglutide on weight outcomes (Wilding 2021, PMID 33567185). For patients still in the middle of the titration ladder (e.g., 5 mg or 7.5 mg tirzepatide, or 1.0 mg semaglutide), stalling often resolves once the next dose step is reached after the standard 4-week interval. For patients already at the maximum label dose (15 mg tirzepatide, 2.4 mg semaglutide) who plateau, the trials do not show that further escalation produces more loss because higher doses were not tested. The 7.2 mg semaglutide dose tested in STEP UP showed only modestly greater loss than 2.4 mg, with more GI adverse events. Dose timing, missed-injection patterns and titration pacing are clinician conversations. None of this is medical advice.

Question 4

Should I switch from Wegovy to Zepbound to break a stall?

Accepted Answer

The head-to-head trial data favor tirzepatide for total weight loss but the gap is smaller than the social-media reputation suggests. SURPASS-2, a head-to-head trial in type 2 diabetes, found tirzepatide 15 mg produced 12.9% weight loss versus 6.2% on semaglutide 1.0 mg at 40 weeks (Frias 2021, PMID 34170647). In direct cross-trial comparison of obesity programs, tirzepatide 15 mg produced 22.5% loss at 72 weeks in SURMOUNT-1 versus 14.9% on semaglutide 2.4 mg at 68 weeks in STEP 1 (Jastreboff 2022, PMID 35658024; Wilding 2021, PMID 33567185). So for a patient stalled near the trial mean on Wegovy, a switch to Zepbound could plausibly add 5-8 percentage points of total loss on average. The switch is not a guaranteed restart of the early-rapid-loss phase. Insurance coverage, titration restart at 2.5 mg, GI side-effect risk during re-titration, and supply at the new dose are the practical hurdles patients describe in switch threads. None of this is medical advice.

Question 5

I am a slow responder on Mounjaro or Zepbound. Should I quit?

Accepted Answer

The trial data show large individual variation, and slow responders frequently catch up later. In SURMOUNT-1 at 72 weeks, 91% of tirzepatide 15 mg patients achieved at least 5% loss and 57% achieved at least 20%, but the corresponding number at week 24 was much lower, meaning much of the response unfolded between months 6 and 18 (Jastreboff 2022, PMID 35658024). STEP 1 reported a similar long tail: 86% of semaglutide patients hit at least 5% loss by week 68 (Wilding 2021, PMID 33567185). Patient-level analyses of STEP and SURMOUNT show that early non-response at week 12 does not reliably predict non-response at week 68; some patients who were near-flat at month 3 reached double-digit loss by month 12. The FDA label and trial protocols use a 5% loss at week 12 as a checkpoint, but it is a soft signal rather than a stop rule. Slow-responder threads on Reddit consistently report breakthrough loss at month 6-9, often coinciding with reaching the next dose step. None of this is medical advice.

Question 6

Did my compounded GLP-1 stop working, or am I just at the natural plateau?

Accepted Answer

Without a head-to-head trial of compounded versus brand at the same dose, you cannot distinguish a potency drop from the natural curve flattening seen in every brand trial. Brand-drug trajectories give the baseline expectation: STEP 1 showed the loss rate slow sharply between week 20 and week 60 on FDA-approved semaglutide 2.4 mg (Wilding 2021, PMID 33567185), and SURMOUNT-1 showed the same flattening on FDA-approved tirzepatide 15 mg between months 9 and 17 (Jastreboff 2022, PMID 35658024). If a patient on compounded semaglutide stalls at month 6-9, the brand trajectory says that timing is normal even when potency is identical. Genuine potency failure would also typically restore food noise, hunger and old eating patterns within days of an injection, not just stall the scale. The FDA-approved drug has known dose and absorption profiles; compounded vials do not have public pharmacokinetic data per batch. A compounded plateau plus rapid return of appetite is a different signal from a compounded plateau with appetite still suppressed. None of this is medical advice.

Question 7

Will I gain the weight back if I plateau and then stop the GLP-1?

Accepted Answer

Yes, in the trials, most of the lost weight comes back within a year of stopping. The STEP 1 extension followed patients for 1 year after withdrawal of semaglutide 2.4 mg and behavioral support, and found that they regained two-thirds of the prior loss by month 120, with cardiometabolic improvements also reverting toward baseline (Wilding 2022, PMID 35441470). STEP 4 made the maintenance question even cleaner: patients who switched to placebo at week 20 regained 6.9% by week 68, while those who continued the drug lost an additional 7.9% over the same window (Rubino 2021, PMID 33755728). SURMOUNT-4 on tirzepatide showed the same pattern: patients switched to placebo regained 14% over 88 weeks while those who continued lost another 5.5% (Aronne 2024, PMID 38078870). The implication: a plateau on the drug is the body holding the loss; stopping the drug is the event most associated with regain. Many clinicians and trials therefore frame GLP-1 therapy as long-term rather than time-limited. None of this is medical advice.

Question 8

Could I be losing fat but not pounds during a GLP-1 plateau?

Accepted Answer

Yes, the body-composition data from the trials suggest scale weight is a coarse tool. In a DXA substudy of STEP 1, patients who lost about 15% of body weight on semaglutide lost roughly 39% of that as lean mass and 61% as fat mass; because so much fat was lost, the proportion of fat in the body actually fell at the end of the study (Wilding 2021, PMID 33567185). Resistance-training patients in particular can be in a phase where lean tissue is being preserved or rebuilt while fat continues to come off, producing a flat scale and a falling waist circumference and clothing size at the same time. Expert reviews emphasize protein intake of about 1.2-1.6 g per kg per day and 2-3 resistance sessions per week to bias the composition shift toward fat loss (Henney 2025, PMID 38710803). Practical signal on Reddit: if the scale is flat but clothes are looser, the tape measure has dropped, and progress photos show change, the plateau is mostly cosmetic in the scale rather than in body fat. None of this is medical advice.

Question 9

Does adding intensive lifestyle changes break a GLP-1 plateau?

Accepted Answer

The dedicated trial that tested this question, SURMOUNT-3, suggests intensive lifestyle therapy plus tirzepatide produces deeper loss than tirzepatide plus standard counseling, especially in patients who had already lost some weight in a lifestyle-only run-in. Adults who completed a 12-week intensive lifestyle intervention and lost at least 5% then received either tirzepatide or placebo for 72 weeks. The tirzepatide arm lost an additional 18.4% on top of the lifestyle phase, for a total of 26.6%, while the placebo arm regained 2.5% (Wadden 2023, PMID 37840095). A separate STEP review confirmed that nearly all STEP trials paired semaglutide with a 500-kcal deficit, 150 min/week of activity, and monthly behavioral counseling, and that the trial-level outcomes are based on that paired protocol, not the drug alone (O'Neil 2022, PMID 36691307). The implication: trial-level loss numbers assume the lifestyle co-intervention. Patients stalled at month 6 who have drifted from the deficit, dropped activity, or stopped logging often see scale movement when those return. None of this is medical advice.

Question 10

How long do GLP-1 plateaus usually last before the scale moves again?

Accepted Answer

Trials do not track individual stall durations directly, but they do show how the average curve flattens and then resumes. In STEP 1, the mean loss rate slowed sharply between week 20 and week 60, with multiple stall-and-resume cycles visible in the patient-level data even though the group mean kept dropping; final mean loss was 14.9% at week 68 (Wilding 2021, PMID 33567185). STEP 5 followed semaglutide patients to 2 years and showed continued small losses past month 12, with the curve approaching a plateau around 15.2% (Garvey 2022, PMID 36216945). SURMOUNT-1 reported 5%, 10%, 15% and 20% threshold crossings spread across the full 72-week period, meaning a substantial share of patients hit their final threshold in months 12-17 rather than months 1-6 (Jastreboff 2022, PMID 35658024). The patient-level pattern on Reddit, consistent with the trial curves, is that stalls of 2-6 weeks are common, stalls of 8-12 weeks are not unusual, and stalls of more than 16 weeks at the same dose with intact behavior are the threshold at which most clinicians revisit dose, drug or lifestyle. None of this is medical advice.

Questions and answers